Recital 176, Commission Decision of 12/12/2023 declaring a concentration to be compatible with the co…

In forcesince 12 Dec 2023

The merged entity would not have the ability to foreclose market access to lactase

manufacturers. First, the parties submit that the merged entity will not have a significant market power in the downstream market both globally and in the EEA to engage in a customer foreclosure strategy. 256 Second, […] Manufacturers (that supply the Parties with non-GM produced lactase) would not be foreclosed from a substantial part of the market. As it currently stands, the Parties’ combined shares for the distribution/commercialization of non-GM produced lactase account for [5-10]% and [5-10]% of the global and EEA sales in the overall lactase market respectively.

257 Third, […] Manufacturers could also choose to distribute their product directly, as they already do in some jurisdictions258 or through a number of distributors they can easily turn to.259 The Parties note that, even if there was an ability to foreclose, it would not be merger specific since pre-Transaction, the Parties supply GM lactase manufactured by Novozymes and the non-GM lactase of the […] Manufacturers and intend to continue to do so post-Transaction.260